OncoSec Medical Inc (ONCSQ)

[lasers]

Long term time survival after treatment can only be proven with the actual time duration. That being said Yervoy has the historical data whereas Keytruda does not. Even though the short-term Keytruda data was great and Yervoy has certain cons against it, the FDA is not convinced yet that Keytruda short term success will not lead to a long term failure. Therefore Keytruda has to go thru the historicsl long term survival proof before the FDA will upgrade its therapy to primary option.

Having said that, IMO IF the short-term success of the Keytruda Combo with EP-IL-12 results in an increase of at least 10% higher survival short-term than keytruda alone, the FDA will want to make additional allowances in endorsing the therapy and granting BLA Commercial license.